Burcin Özdirik

616 total citations
24 papers, 319 citations indexed

About

Burcin Özdirik is a scholar working on Epidemiology, Hepatology and Oncology. According to data from OpenAlex, Burcin Özdirik has authored 24 papers receiving a total of 319 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Epidemiology, 11 papers in Hepatology and 10 papers in Oncology. Recurrent topics in Burcin Özdirik's work include Neuroendocrine Tumor Research Advances (9 papers), Lung Cancer Research Studies (8 papers) and Liver Diseases and Immunity (8 papers). Burcin Özdirik is often cited by papers focused on Neuroendocrine Tumor Research Advances (9 papers), Lung Cancer Research Studies (8 papers) and Liver Diseases and Immunity (8 papers). Burcin Özdirik collaborates with scholars based in Germany, United States and United Kingdom. Burcin Özdirik's co-authors include Frank Tacke, Christoph Roderburg, Alexander Wree, Münevver Demir, Raphael Mohr, Henning Jann, Tobias Müller, Michael Sigal, Bertram Wiedenmann and Linda Hammerich and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Hepatology.

In The Last Decade

Burcin Özdirik

23 papers receiving 316 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Burcin Özdirik Germany 12 154 112 105 69 56 24 319
Ryo Muranushi Japan 12 95 0.6× 203 1.8× 50 0.5× 99 1.4× 60 1.1× 41 341
Shuichi Tsukamoto Japan 11 58 0.4× 132 1.2× 62 0.6× 77 1.1× 107 1.9× 23 333
Ryu Otao Japan 10 150 1.0× 122 1.1× 236 2.2× 177 2.6× 45 0.8× 16 378
Xiaoyun Zhang China 11 107 0.7× 68 0.6× 78 0.7× 49 0.7× 96 1.7× 43 305
Ewa Pomianowska Norway 12 104 0.7× 318 2.8× 68 0.6× 214 3.1× 38 0.7× 14 395
Xavier Chopin‐Laly France 10 165 1.1× 347 3.1× 87 0.8× 216 3.1× 66 1.2× 13 498
Satoshi Moriya Japan 11 141 0.9× 85 0.8× 193 1.8× 58 0.8× 42 0.8× 31 305
F Latteri Italy 8 107 0.7× 63 0.6× 157 1.5× 76 1.1× 34 0.6× 24 301
Olusola Olusesan Faluyi United Kingdom 11 60 0.4× 163 1.5× 23 0.2× 50 0.7× 55 1.0× 29 292

Countries citing papers authored by Burcin Özdirik

Since Specialization
Citations

This map shows the geographic impact of Burcin Özdirik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Burcin Özdirik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Burcin Özdirik more than expected).

Fields of papers citing papers by Burcin Özdirik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Burcin Özdirik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Burcin Özdirik. The network helps show where Burcin Özdirik may publish in the future.

Co-authorship network of co-authors of Burcin Özdirik

This figure shows the co-authorship network connecting the top 25 collaborators of Burcin Özdirik. A scholar is included among the top collaborators of Burcin Özdirik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Burcin Özdirik. Burcin Özdirik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Phan, Minh D., Burcin Özdirik, Hilmar Berger, et al.. (2025). Soluble Urokinase Plasminogen Activator Receptor Predicts Survival and Hepatic Decompensation in Advanced Hepatocellular Carcinoma. Liver International. 45(6). e70121–e70121. 1 indexed citations
2.
Özdirik, Burcin, W Veltzke-Schlieker, Hilmar Berger, et al.. (2024). Long-term impact of scheduled regular endoscopic interventions for patients with primary sclerosing cholangitis. Hepatology Communications. 8(9). 1 indexed citations
3.
Guillot, Adrien, Milessa Silva Afonso, Abhishek Aggarwal, et al.. (2023). Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression. Hepatology. 78(1). 150–166. 60 indexed citations
4.
Özdirik, Burcin & Bernd Schnabl. (2023). Microbial Players in Primary Sclerosing Cholangitis: Current Evidence and Concepts. Cellular and Molecular Gastroenterology and Hepatology. 17(3). 423–438. 11 indexed citations
5.
Özdirik, Burcin, et al.. (2023). Biliary microbial patterns in primary sclerosing cholangitis are linked to poorer transplant-free survival. Hepatology Communications. 7(6). 6 indexed citations
6.
Özdirik, Burcin, et al.. (2022). Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis. Journal of Clinical Medicine. 11(9). 2479–2479. 2 indexed citations
7.
Özdirik, Burcin, Lynn Jeanette Savic, Raphael Mohr, et al.. (2021). Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma. Medicine. 100(24). e26377–e26377. 14 indexed citations
8.
Geisler, Lukas, Raphael Mohr, Joeri Lambrecht, et al.. (2021). The Role of miRNA in the Pathophysiology of Neuroendocrine Tumors. International Journal of Molecular Sciences. 22(16). 8569–8569. 13 indexed citations
9.
Özdirik, Burcin, Tobias Müller, Alexander Wree, Frank Tacke, & Michael Sigal. (2021). The Role of Microbiota in Primary Sclerosing Cholangitis and Related Biliary Malignancies. International Journal of Molecular Sciences. 22(13). 6975–6975. 34 indexed citations
10.
11.
Mohr, Raphael, Burcin Özdirik, Joeri Lambrecht, et al.. (2021). From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis. International Journal of Molecular Sciences. 22(3). 1492–1492. 21 indexed citations
12.
Özdirik, Burcin, Henning Jann, Philip Bischoff, et al.. (2021). PD-L1 – inhibitors in neuroendocrine neoplasia. Medicine. 100(1). e23835–e23835. 10 indexed citations
13.
Mohr, Raphael, Burcin Özdirik, Joeri Lambrecht, et al.. (2021). Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma. Frontiers in Immunology. 12. 652172–652172. 23 indexed citations
14.
Özdirik, Burcin, Antonin Kayser, Lynn Jeanette Savic, et al.. (2020). Primary Neuroendocrine Neoplasms of the Breast: Case Series and Literature Review. Cancers. 12(3). 733–733. 22 indexed citations
15.
Mohr, Raphael, Burcin Özdirik, Alexander Wree, et al.. (2020). In Vivo Models for Cholangiocarcinoma—What Can We Learn for Human Disease?. International Journal of Molecular Sciences. 21(14). 4993–4993. 11 indexed citations
16.
Mohr, Raphael, Lukas Geisler, Alexander Wree, et al.. (2020). Serum levels of miR-223 but not miR-21 are decreased in patients with neuroendocrine tumors. PLoS ONE. 15(12). e0244504–e0244504. 4 indexed citations
17.
Özdirik, Burcin, Lukas Geisler, Raphael Mohr, et al.. (2020). Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies. Journal of Clinical Medicine. 9(6). 1647–1647. 10 indexed citations
18.
Özdirik, Burcin, Raphael Mohr, Lukas Geisler, et al.. (2020). Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study. Journal of Clinical Medicine. 9(9). 2881–2881. 8 indexed citations
19.
Detjen, Katharina, Linda Hammerich, Burcin Özdirik, et al.. (2020). Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions. Neuroendocrinology. 111(3). 217–236. 16 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ryo Muranushi Breakdown of academic impact, for papers by Shuichi Tsukamoto Breakdown of academic impact, for papers by Ryu Otao Breakdown of academic impact, for papers by Xiaoyun Zhang Breakdown of academic impact, for papers by Ewa Pomianowska Breakdown of academic impact, for papers by Xavier Chopin‐Laly Breakdown of academic impact, for papers by Satoshi Moriya Breakdown of academic impact, for papers by F Latteri Breakdown of academic impact, for papers by Olusola Olusesan Faluyi
Rankless by CCL
2026